Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2011 08:02 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Initiates Randomized Phase 2 Trial of IPI-504, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer

CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the initiation of a Phase 2 clinical trial of retaspimycin hydrochloride (HCl), also...
May 19, 2011 07:58 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Clinical Data to be Presented at ASCO

CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that clinical data for IPI-926, its novel Smoothened antagonist, and retaspimycin...
May 10, 2011 16:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Reports First Quarter 2011 Financial Results

— Reaffirms 2011 Financial Guidance and Provides Additional Details — — Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer...
May 03, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces the Date of Its First Quarter 2011 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., May 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, May 10, 2011 at 4:30 p.m. ET. During the call, management will...
April 11, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Appointment of Joshua Hamermesh as Vice President, Business and Corporate Development

CAMBRIDGE, Mass., April 11, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the appointment of Joshua D. Hamermesh as vice president, business and corporate...
April 07, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals to Present at BioCentury Future Leaders Conference

CAMBRIDGE, Mass., April 7, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at BioCentury's 18th Annual Future Leaders in the Biotech Industry Conference on...
April 03, 2011 13:36 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Reports New Preclinical Data for IPI-926 at AACR Supporting Development in Chondrosarcoma

CAMBRIDGE, Mass., April 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results for its novel Smoothened antagonist, IPI-926, in a preclinical...
March 23, 2011 08:01 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Present New Preclinical Data on IPI-926, a Novel Smoothened Antagonist Targeting the Hedgehog Pathway, at Upcoming AACR Meeting

CAMBRIDGE, Mass., March 23, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that the company will present new preclinical data supporting ongoing development of...
March 15, 2011 16:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Provides Company Update and Reports Fourth Quarter and Full-Year 2010 Financial Results

IPI-926 Advancing in Two Phase 2 Trials, Underscoring Pipeline Momentum Cash Runway Into 2014 Enables Advancement of Product Candidates to Key Inflection Points Company Changes Accounting...
March 08, 2011 08:30 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces the Date of Its Fourth Quarter 2010 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., March 8, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, March 15, 2011 at 4:30 p.m. ET. During the call, management...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right